$CRVO
CervoMed Inc.

2023 Q4 Form 10-Q Financial Statement

#000143774923031374 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $2.491M $1.526M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.116M $2.410M $2.125M
YoY Change -9.75% 13.42% 10.09%
% of Gross Profit
Research & Development $2.855M $1.791M $798.2K
YoY Change 49.93% 124.43% -62.09%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $4.971M $4.202M $798.2K
YoY Change 17.0% 426.35% -62.09%
Operating Profit -$2.675M -$2.923M
YoY Change -8.48% -76.97%
Interest Expense $118.7K $50.00K $124.7K
YoY Change -31.36% -59.91% 145.93%
% of Operating Profit
Other Income/Expense, Net -$600.00 $4.825M $21.43K
YoY Change 22416.41%
Pretax Income -$2.362M $2.150M -$2.798M
YoY Change -42.04% -176.83% -77.87%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.362M $2.150M -$2.798M
YoY Change -42.04% -176.84% -77.06%
Net Earnings / Revenue -94.85% 140.87%
Basic Earnings Per Share $0.65 -$1.37
Diluted Earnings Per Share -$0.38 -$0.70 -$1.372M
COMMON SHARES
Basic Shares Outstanding 5.675M 2.040M 2.039M
Diluted Shares Outstanding 3.767M 518.1K

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.793M $10.42M $25.86M
YoY Change -65.4% -59.7% -35.89%
Cash & Equivalents $7.793M $10.42M $6.587M
Short-Term Investments $19.27M
Other Short-Term Assets $1.257M $143.6K $464.9K
YoY Change 1017.78% -69.11% 22.3%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.965M $11.84M $26.32M
YoY Change -55.98% -55.01% -35.35%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.770K $194.4K $0.00
YoY Change -100.0%
Total Long-Term Assets $7.770K $194.4K $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $9.965M $11.84M $26.32M
Total Long-Term Assets $7.770K $194.4K $0.00
Total Assets $9.973M $12.04M $26.32M
YoY Change -55.94% -54.27% -35.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $662.5K $533.8K $807.4K
YoY Change -41.26% -33.89% 19.08%
Accrued Expenses $1.933M $1.380M $1.463M
YoY Change 49.92% -5.69% -29.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.596M $2.460M $2.271M
YoY Change 7.38% 8.34% -17.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.596M $2.460M $2.271M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.596M $2.464M $2.271M
YoY Change 7.38% 8.5% -17.4%
SHAREHOLDERS EQUITY
Retained Earnings -$54.40M -$52.10M -$141.5M
YoY Change -62.64% -63.19% 11.85%
Common Stock $5.674K $5.674K $165.7M
YoY Change 178.14% -100.0% 0.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.377M $9.574M $24.05M
YoY Change
Total Liabilities & Shareholders Equity $9.973M $12.04M $26.32M
YoY Change -55.94% -54.27% -35.61%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$2.362M $2.150M -$2.798M
YoY Change -42.04% -176.84% -77.06%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities -$2.540M $2.700M -$2.759M
YoY Change -26.88% -197.87% -7.19%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $3.380M
YoY Change
Cash From Investing Activities $3.380M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -90.89K 11.24M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.540M 2.700M -2.759M
Cash From Investing Activities 3.380M
Cash From Financing Activities -90.89K 11.24M 0.000
Net Change In Cash -2.631M 13.94M 621.3K
YoY Change -174.6% 2143.68% -120.9%
FREE CASH FLOW
Cash From Operating Activities -$2.540M $2.700M -$2.759M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Assets Current
AssetsCurrent
11843420 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4093579 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
533790 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001053691
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023Q1 us-gaap Government Assistance Transaction Duration
GovernmentAssistanceTransactionDuration
P3Y
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
194443 usd
CY2023Q3 us-gaap Assets
Assets
12037863 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
97302 usd
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
547051 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1382822 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
12414000 usd
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
24287211 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5674354
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5674354
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
518140
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
518140
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
5674 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
518 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61646917 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18983339 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52078391 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52268916 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
9574200 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-33285059 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12037863 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4157706 usd
CY2023Q3 us-gaap Revenues
Revenues
1526482 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
4654294 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1791487 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
330543 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5583149 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
955784 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2410124 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
573511 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4403590 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1580927 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4201611 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
904054 usd
us-gaap Operating Expenses
OperatingExpenses
9986739 usd
us-gaap Operating Expenses
OperatingExpenses
2536711 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2675129 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-904054 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5332445 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4777824 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1769093 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
21519 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
100778 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
30157 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21431 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5522970 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1738936 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
2150362 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-882623 usd
us-gaap Net Income Loss
NetIncomeLoss
190525 usd
us-gaap Net Income Loss
NetIncomeLoss
-4275647 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.25
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3308302
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
518140
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1458415
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
518140
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.70
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.25
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3766700
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
518140
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2209407
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
518140
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-35111404 usd
CY2023Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
24287211 usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
6989749 usd
CY2023Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
10339114 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
810000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
109168 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
2150362 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9574200 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-33285059 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
24287211 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
6989749 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
10339114 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
810000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
242660 usd
us-gaap Net Income Loss
NetIncomeLoss
190525 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9574200 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-31038407 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
82384 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-882623 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-31838646 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-27943363 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
252847 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
127517 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-31838646 usd
us-gaap Net Income Loss
NetIncomeLoss
190525 usd
us-gaap Net Income Loss
NetIncomeLoss
-4275647 usd
us-gaap Share Based Compensation
ShareBasedCompensation
242660 usd
us-gaap Share Based Compensation
ShareBasedCompensation
252847 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
127516 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-5424251 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
1769000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1549061 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-111496 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
382675 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
57347 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
547051 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4911393 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1880229 usd
crvo Proceeds From Net Assets Assumed In Connection With Reverse Recapitalization
ProceedsFromNetAssetsAssumedInConnectionWithReverseRecapitalization
11887757 usd
crvo Proceeds From Net Assets Assumed In Connection With Reverse Recapitalization
ProceedsFromNetAssetsAssumedInConnectionWithReverseRecapitalization
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
810000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1455268 usd
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
-0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11242489 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6331096 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1880229 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4093579 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6666338 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10424675 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4786109 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
24287211 usd
crvo Merger Costs In Accounts Payable And Accrued Expenses
MergerCostsInAccountsPayableAndAccruedExpenses
93375 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><a href="#" id="notes" title="notes"></a><b>1. The Company and Description of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company, a corporation organized under the laws of the state of Delaware and headquartered in Boston, Massachusetts, is a clinical-stage biotechnology company developing treatments for degenerative diseases of the brain. The Company is currently developing its product candidate neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38α. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders, and is currently being evaluated in a Phase 2b study in patients with DLB.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On March 30, 2023, the Company, Merger Sub, and EIP entered into the Merger Agreement (Note 4), pursuant to which, at the Effective Time, Merger Sub merged with and into EIP, with EIP surviving the Merger as a wholly-owned subsidiary of the Company. In connection with the Merger, on August 16, 2023, the Company changed its corporate name from “Diffusion Pharmaceuticals Inc.” to “CervoMed Inc.”</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">On August 16, 2023, Diffusion approved a one-for-1.5 reverse stock split which was consummated for historical Diffusion shares in connection with the Merger. In addition, upon consummation of the Merger, all historical EIP shares were adjusted using an exchange ratio of .1151. All information in the accompanying unaudited condensed consolidated interim financial statements and notes thereto regarding share amounts of common stock, price per share of common stock and the conversion factor for preferred stock into common stock have been adjusted to reflect the application of the reverse stock split and the exchange ratio on a retroactive basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All shares of EIP common stock outstanding immediately prior to the Effective Time, after giving effect to the conversion of EIP preferred stock and the Convertible Notes (and excluding shares held as treasury stock by EIP, shares held or owned by the Company and any dissenting shares), converted into the right to receive, in the aggregate, 4,314,033 shares of the Company’s common stock and prefunded warrants to purchase 495,995, based on an exchange ratio of 0.1151.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52100000 usd
CY2023Q1 us-gaap Government Assistance Amount Cumulative
GovernmentAssistanceAmountCumulative
21000000.0 usd
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
800000 usd
us-gaap Fiscal Period
FiscalPeriod
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Unaudited condensed consolidated interim financial statements</i></b></p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying unaudited condensed consolidated interim financial statements have been prepared by the Company in accordance with US GAAP for interim information and pursuant to the rules and regulations of the SEC. Accordingly, certain information and footnote disclosures normally included in unaudited condensed consolidated interim financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements and related notes for the year ended December 31, 2022, which begin on page F-30 of the Difffusions Amended Registration Statement on Form S-4 as filed with the SEC on July 11, 2023.</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The unaudited condensed consolidated interim financial statements have been prepared on the same basis as the audited financial statements, and in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods. The results of operations for any interim period are not necessarily indicative of the results to be expected for the full fiscal year.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of unaudited condensed consolidated interim financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, grant revenue, expenses, and related disclosures. On an ongoing basis, the Company’s management evaluates its estimates, including estimates related to money market accounts, clinical trial accruals, stock-based compensation expense, grant revenue, Convertible Notes, and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ significantly from those estimates or assumptions.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company maintains its cash and cash equivalent balances with financial institutions that management believes are creditworthy. The Company has no financial instruments with off-balance-sheet risk of loss. The Company has not experienced any losses in such accounts.</p>
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
143619 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
12414000 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
10025000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
5424251 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-2389000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
-6989749 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
12414000 usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
11768000 usd
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
12414000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
4778251 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-0 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
-6989749 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
12414000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
2150362 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-882623 usd
us-gaap Net Income Loss
NetIncomeLoss
190525 usd
us-gaap Net Income Loss
NetIncomeLoss
-4275647 usd
CY2023Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
4778251 usd
CY2022Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
-0 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
5424251 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
-0 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2627889 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-882623 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5233726 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4275647 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3308302
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
518140
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1458415
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
518140
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
458398
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
750992
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3766700
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
518140
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2209407
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
518140
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.65
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.25
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.70
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.25
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
927797
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3516650
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5674277
CY2023Q3 crvo Prepaid Clinical Expenses
PrepaidClinicalExpenses
670851 usd
CY2022Q4 crvo Prepaid Clinical Expenses
PrepaidClinicalExpenses
0 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
604275 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
9937 usd
CY2023Q3 us-gaap Prepaid Rent
PrepaidRent
0 usd
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
2455 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
51735 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1418745 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
64127 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
492772 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
206675 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
696570 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
364070 usd
CY2023Q3 crvo Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
71979 usd
CY2022Q4 crvo Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
23185 usd
CY2023Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
121501 usd
CY2022Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
50322 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1382822 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
644252 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
8000 usd
CY2023Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1059768 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54228753 usd
CY2023Q2 us-gaap Assets
Assets
3364216 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3364216 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-35111404 usd
CY2023Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
638018 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
3000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
23000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
38000 usd
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.90 pure
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04 pure
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
3946 usd
us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
1360244
CY2023Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
63422
CY2023Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
12.78
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
800000 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
598457
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
109168 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
82384 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
242660 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
252847 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
114516
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
52574
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
313.67
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
162250
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.33
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
329340
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
61.73
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
148912
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
111.77
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52803252 usd
CY2023Q1 us-gaap Assets
Assets
3943495 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3943495 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-33748155 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1993466 usd
us-gaap Operating Expenses
OperatingExpenses
5785128 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2657316 usd
us-gaap Net Income Loss
NetIncomeLoss
-1959837 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1000913 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
2834187 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1426319 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-534336 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001437749-23-031374-index-headers.html Edgar Link pending
0001437749-23-031374-index.html Edgar Link pending
0001437749-23-031374.txt Edgar Link pending
0001437749-23-031374-xbrl.zip Edgar Link pending
crvo-20230930.xsd Edgar Link pending
dffn20230930_10q.htm Edgar Link pending
crvo-20230930_cal.xml Edgar Link unprocessable
crvo-20230930_def.xml Edgar Link unprocessable
crvo-20230930_lab.xml Edgar Link unprocessable
ex_592326.htm Edgar Link pending
ex_592327.htm Edgar Link pending
ex_592328.htm Edgar Link pending
ex_592329.htm Edgar Link pending
ex_593341.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
dffn20230930_10q_htm.xml Edgar Link completed
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
crvo-20230930_pre.xml Edgar Link unprocessable